--- title: "Satellos Bioscience Unveils Positive Interim SAT-3247 Data in Duchenne Muscular Dystrophy at MDA 2026" type: "News" locale: "en" url: "https://longbridge.com/en/news/278546012.md" description: "Satellos Bioscience (TSE:MSCL) reported positive interim data for its lead candidate SAT-3247 in Duchenne muscular dystrophy at the MDA Clinical Conference on March 10, 2026. The Phase 2 TRAILHEAD trial showed improvements in handgrip strength and stable elbow and shoulder strength, particularly in participants with higher baseline muscle mass. The company plans to test the drug earlier in disease progression. Analyst ratings suggest a Buy with a C$40.00 price target, though concerns about financial performance and cash burn persist. Satellos focuses on developing therapies for muscle degeneration." datetime: "2026-03-10T11:28:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278546012.md) - [en](https://longbridge.com/en/news/278546012.md) - [zh-HK](https://longbridge.com/zh-HK/news/278546012.md) --- # Satellos Bioscience Unveils Positive Interim SAT-3247 Data in Duchenne Muscular Dystrophy at MDA 2026 ### Claim 70% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Satellos Bioscience ( (TSE:MSCL) ) has provided an update. On March 10, 2026, Satellos Bioscience reported interim data for its lead candidate SAT-3247 in Duchenne muscular dystrophy at the Muscular Dystrophy Association Clinical & Scientific Conference, highlighting continued improvements in handgrip strength and stable elbow and shoulder strength in adults enrolled in the ongoing Phase 2 TRAILHEAD trial. The company also said greater strength gains were seen in participants with higher baseline muscle mass, reinforcing its strategy to test the drug earlier in disease progression in the pediatric BASECAMP study, while additional biomarker and preclinical data, including reductions in established DMD biomarkers and improved muscle strength in an FSHD mouse model, support the broader clinical potential of SAT-3247 as a disease-modifying therapy and underpin the continuation of its current clinical programs. Serum proteomic analysis from the completed 28-day CL-101 Phase 1a/b study showed consistent reductions in key DMD biomarkers such as AK1, CA3, ENO3, MB and ANKRD2 within two weeks of dosing, changes that were observed across all participants with comparable magnitude. Satellos also unveiled a novel regenerative index tool based on biomarker signatures to assess muscle regeneration, now embedded in the BASECAMP protocol, and presented preclinical data demonstrating significant 12-week strength gains in an FSHD mouse model, findings that together strengthen the scientific rationale for SAT-3247 and may enhance the company’s positioning in the competitive neuromuscular disease field while signaling incremental validation for investors and patients tracking the progress of its clinical pipeline. The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$40.00 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page. **Spark’s Take on TSE:MSCL Stock** According to Spark, TipRanks’ AI Analyst, TSE:MSCL is a Neutral. The score is held down primarily by weak financial performance (pre-revenue, large losses, and heavy cash burn with ongoing funding risk). Technicals are supportive due to a clear uptrend, but overbought signals temper that strength. Valuation is also constrained by negative earnings and no dividend support. To see Spark’s full report on TSE:MSCL stock, click here. **More about Satellos Bioscience** Satellos Bioscience Inc. is a Toronto-based, clinical-stage biotechnology company focused on developing small-molecule drugs to restore natural muscle repair and regeneration in degenerative muscle diseases. Its lead candidate, SAT-3247, is an oral AAK1-targeting therapy in Phase 2 development for Duchenne muscular dystrophy (DMD), with additional potential applications in other muscle disorders such as facioscapulohumeral muscular dystrophy (FSHD). **Average Trading Volume:** 35,042 **Technical Sentiment Signal:** Buy **Current Market Cap:** C$243.8M See more insights into MSCL stock on TipRanks’ Stock Analysis page. ### Related Stocks - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [ASMB.US](https://longbridge.com/en/quote/ASMB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [TBIO.US](https://longbridge.com/en/quote/TBIO.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) ## Related News & Research - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [](https://longbridge.com/en/news/286807703.md) - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md) - [](https://longbridge.com/en/news/286787081.md)